Does the use of statins improve outcomes in coronary artery bypass graft surgery?

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) are one of the most frequently prescribed medications throughout the world with beneficial effects that extend beyond their lipid-lowering activity. It has been suggested that statins may offer a simple and cost-effective strategy to reduce some of the complications that occur in association with coronary artery bypass graft (CABG) surgery. Limited existing randomized trial evidence in the setting of cardiac surgery suggests that statins may reduce the incidence of postoperative atrial fibrillation. However, any effect of statins on other outcomes is less clear. The clinical significance of specific statin agent and dose, acute statin withdrawal and the potential benefits associated with statin reloading remain important yet currently unresolved issues. Despite limited high-quality evidence, class I recommendations have been made that all patients undergoing coronary artery bypass graft surgery should receive statin therapy unless contraindicated.
Original languageEnglish
Pages (from-to)1285 - 1288
Number of pages4
JournalExpert Review of Cardiovascular Therapy
Volume13
Issue number12
DOIs
Publication statusPublished - 2015

Cite this

@article{6af4c3e577b84c4c935101e9a90f5784,
title = "Does the use of statins improve outcomes in coronary artery bypass graft surgery?",
abstract = "Statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) are one of the most frequently prescribed medications throughout the world with beneficial effects that extend beyond their lipid-lowering activity. It has been suggested that statins may offer a simple and cost-effective strategy to reduce some of the complications that occur in association with coronary artery bypass graft (CABG) surgery. Limited existing randomized trial evidence in the setting of cardiac surgery suggests that statins may reduce the incidence of postoperative atrial fibrillation. However, any effect of statins on other outcomes is less clear. The clinical significance of specific statin agent and dose, acute statin withdrawal and the potential benefits associated with statin reloading remain important yet currently unresolved issues. Despite limited high-quality evidence, class I recommendations have been made that all patients undergoing coronary artery bypass graft surgery should receive statin therapy unless contraindicated.",
author = "McIlroy, {David Richard} and Myles, {Paul S}",
year = "2015",
doi = "10.1586/14779072.2015.1099434",
language = "English",
volume = "13",
pages = "1285 -- 1288",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Taylor & Francis",
number = "12",

}

Does the use of statins improve outcomes in coronary artery bypass graft surgery? / McIlroy, David Richard; Myles, Paul S.

In: Expert Review of Cardiovascular Therapy, Vol. 13, No. 12, 2015, p. 1285 - 1288.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Does the use of statins improve outcomes in coronary artery bypass graft surgery?

AU - McIlroy, David Richard

AU - Myles, Paul S

PY - 2015

Y1 - 2015

N2 - Statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) are one of the most frequently prescribed medications throughout the world with beneficial effects that extend beyond their lipid-lowering activity. It has been suggested that statins may offer a simple and cost-effective strategy to reduce some of the complications that occur in association with coronary artery bypass graft (CABG) surgery. Limited existing randomized trial evidence in the setting of cardiac surgery suggests that statins may reduce the incidence of postoperative atrial fibrillation. However, any effect of statins on other outcomes is less clear. The clinical significance of specific statin agent and dose, acute statin withdrawal and the potential benefits associated with statin reloading remain important yet currently unresolved issues. Despite limited high-quality evidence, class I recommendations have been made that all patients undergoing coronary artery bypass graft surgery should receive statin therapy unless contraindicated.

AB - Statins (3-hydroxy-3-methylglutaryl CoA reductase inhibitors) are one of the most frequently prescribed medications throughout the world with beneficial effects that extend beyond their lipid-lowering activity. It has been suggested that statins may offer a simple and cost-effective strategy to reduce some of the complications that occur in association with coronary artery bypass graft (CABG) surgery. Limited existing randomized trial evidence in the setting of cardiac surgery suggests that statins may reduce the incidence of postoperative atrial fibrillation. However, any effect of statins on other outcomes is less clear. The clinical significance of specific statin agent and dose, acute statin withdrawal and the potential benefits associated with statin reloading remain important yet currently unresolved issues. Despite limited high-quality evidence, class I recommendations have been made that all patients undergoing coronary artery bypass graft surgery should receive statin therapy unless contraindicated.

UR - http://dx.doi.org/10.1586/14779072.2015.1099434

U2 - 10.1586/14779072.2015.1099434

DO - 10.1586/14779072.2015.1099434

M3 - Article

VL - 13

SP - 1285

EP - 1288

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 12

ER -